SEC Form SC 13G filed by Treace Medical Concepts Inc.

11/8/24 3:44:13 PM ET

Medical/Dental Instruments

Health Care

Get the next $TMCI alert in real time by email

SC 13G 1 TreaceMedicalConceptsTMCI.txt MS INITIAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* TREACE MEDICAL CONCEPTS, INC. ----------------------------------------------------- (Name of Issuer) Common Stock ----------------------------------------------------- (Title of Class of Securities) 89455T109 ----------------------------------------------------- (CUSIP Number) September 30, 2024 ----------------------------------------------------- (Date Of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1745 (3-06) CUSIP No.89455T109 13G Page 2 of 5 Pages -------------------------------------------------------------------------------- 1. NAME OF REPORTING PERSON: I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: Morgan Stanley I.R.S. # 36-3145972 -------------------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP: (a) [ ] (b) [ ] -------------------------------------------------------------------------------- 3. SEC USE ONLY: -------------------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware. -------------------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER: SHARES 0 BENEFICIALLY -------------------------------------------------------------- OWNED BY 6. SHARED VOTING POWER: EACH 3,192,349 REPORTING -------------------------------------------------------------- PERSON 7. SOLE DISPOSITIVE POWER: WITH: 0 -------------------------------------------------------------- 8. SHARED DISPOSITIVE POWER: 3,213,991 -------------------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 3,213,991 -------------------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES: [ ] -------------------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9): 5.2% -------------------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON: HC, CO -------------------------------------------------------------------------------- CUSIP No.89455T109 13G Page 3 of 5 Pages -------------------------------------------------------------------------------- Item 1. (a) Name of Issuer: TREACE MEDICAL CONCEPTS, INC. -------------------------------------------------------------- (b) Address of Issuer's Principal Executive Offices: 100 PALMETTO PARK PLACE PONTE VEDRA FL 32081 UNITED STATES OF AMERICA -------------------------------------------------------------- Item 2. (a) Name of Person Filing: (1) Morgan Stanley -------------------------------------------------------------- (b) Address of Principal Business Office, or if None, Residence: (1) 1585 Broadway, New York, NY 10036 -------------------------------------------------------------- (c) Citizenship: (1) Delaware. -------------------------------------------------------------- (d) Title of Class of Securities: Common Stock -------------------------------------------------------------- (e) CUSIP Number: 89455T109 -------------------------------------------------------------- Item 3. If this statement is filed pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) [ ] An investment adviser in accordance with Sections 240.13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F); (g) [x] A parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G); (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] A non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J); (k) [ ] Group, in accordance with sections 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with sections 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Not Applicable CUSIP No.89455T109 13G Page 4 of 5 Pages -------------------------------------------------------------------------------- Item 4. Ownership as of September 30, 2024.* (a) Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s). (b) Percent of Class: See the response(s) to Item 11 on the attached cover page(s). (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s). (ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s). (iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s). (iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s). Item 5. Ownership of Five Percent or Less of a Class. Not Applicable Item 6. Ownership of More Than Five Percent on Behalf of Another Person. Not Applicable Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8. Identification and Classification of Members of the Group. Not Applicable Item 9. Notice of Dissolution of Group. Not Applicable Item 10. Certification. (1) By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release. CUSIP No.89455T109 13G Page 5 of 5 Pages -------------------------------------------------------------------------------- Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: November 08, 2024 Signature: /s/ Christopher O'Hara -------------------------------------------------------------------- Name/Title: Christopher O'Hara/Authorized Signatory, Morgan Stanley -------------------------------------------------------------------- MORGAN STANLEY

Get the next $TMCI alert in real time by email

Recent Analyst Ratings for

$TMCI

Date	Price Target	Rating	Analyst
5/16/2024	$16.00 → $6.50	Buy → Neutral	UBS
5/8/2024	$15.00 → $5.50	Overweight → Equal-Weight	Morgan Stanley
5/8/2024	$17.00 → $7.00	Buy → Hold	Truist
5/8/2024	$15.00 → $6.00	Buy → Hold	Stifel
5/8/2024	$15.00 → $8.00	Overweight → Neutral	JP Morgan
5/8/2024		Buy → Neutral	BTIG Research
9/29/2023	$24.00	Buy	UBS
5/1/2023	$33.00	Buy	Truist

More analyst ratings

SEC Form SC 13G filed by Treace Medical Concepts Inc.

Chat with this insight

Recent Analyst Ratings for $TMCI

$TMCI Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Treace John T. bought $265,630 worth of shares (50,000 units at $5.31), increasing direct ownership by 0.77% to 6,523,095 units (SEC Form 4)

Director Treace James T bought $501,035 worth of shares (84,000 units at $5.96), increasing direct ownership by 7% to 1,223,441 units (SEC Form 4)

Chief Executive Officer Treace John T. bought $510,314 worth of shares (85,000 units at $6.00), increasing direct ownership by 1% to 6,473,095 units (SEC Form 4)

$TMCI Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Treace Medical Concepts Inc.

Amendment: SEC Form SC 13G/A filed by Treace Medical Concepts Inc.

Amendment: SEC Form SC 13G/A filed by Treace Medical Concepts Inc.

$TMCI SEC Filings

SEC Form 10-Q filed by Treace Medical Concepts Inc.

Treace Medical Concepts Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Treace Medical Concepts Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

$TMCI Financials

Live finance-specific insights

Treace to Report Third Quarter 2024 Financial Results on November 5, 2024

Treace to Report Second Quarter 2024 Financial Results on August 6, 2024

Treace to Report First Quarter 2024 Financial Results

$TMCI Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Treace Medical Concepts downgraded by UBS with a new price target

Treace Medical Concepts downgraded by Morgan Stanley with a new price target

Treace Medical Concepts downgraded by Truist with a new price target

$TMCI Press Releases

Fastest customizable press release news feed in the world

Treace Medical Concepts Reports Third Quarter 2024 Financial Results

Treace Announces Participation in the UBS Global Healthcare Conference

Treace Comments on CMS' 2025 Final Rule for Hospital Outpatient and ASC Settings

$TMCI Market Insights

Live Market Insights

$TMCI Leadership Updates

Live Leadership Updates

$TMCI Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Beyond The Numbers: 8 Analysts Discuss Treace Medical Concepts Stock

Truist Securities Maintains Hold on Treace Medical Concepts, Raises Price Target to $9

Morgan Stanley Maintains Equal-Weight on Treace Medical Concepts, Raises Price Target to $8

Treace Medical Concepts Appoints Nathan Minnich as Senior Vice President, Marketing

Treace Appoints Julie Dewey as Chief Communications and Investor Relations Officer

Treace Medical Concepts Appoints New Directors

Chief Legl & Comp Off, CorpSec Elder Scot Michael was granted 200,000 shares, increasing direct ownership by 84% to 437,915 units (SEC Form 4)

Chief Executive Officer Treace John T. bought $265,630 worth of shares (50,000 units at $5.31), increasing direct ownership by 0.77% to 6,523,095 units (SEC Form 4)

Chief Innovation Officer Scanlan Sean F. exercised 33,750 shares at a strike of $0.10, increasing direct ownership by 16% to 250,074 units (SEC Form 4)

Recent Analyst Ratings for
$TMCI

$TMCI
Insider Purchases

$TMCI
Large Ownership Changes

$TMCI
SEC Filings

$TMCI
Financials

$TMCI
Analyst Ratings

$TMCI
Press Releases

$TMCI
Market Insights

$TMCI
Leadership Updates

$TMCI
Insider Trading